

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

JMT203 (ANTI-GFRAL MONOCLONAL ANTIBODY) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the antibody drug JMT203 (the “**Product**”) independently developed by Shanghai JMT-BIO Technology Co., Ltd.* (上海津曼特生物科技有限公司), a subsidiary of the Company, has been approved by the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the U.S. Previously, the Product obtained approval from the National Medical Products Administration of the People’s Republic of China in June 2023 and is currently undergoing clinical trials in China.

The Product independently developed by the Group is a recombinant humanised monoclonal antibody against GDNF family receptor alpha like (GFRAL), which can effectively antagonise the GDF15-GFRAL/RET signal and regulate appetite and metabolism. It can potentially reverse or alleviate symptoms of cachexia, such as weight loss, anorexia and muscular atrophy caused by tumors and chemotherapy drugs, thereby effectively improving the quality of life of tumor patients. The indication for this approval is cancer cachexia. Preclinical studies demonstrated that the Product had good safety profile and was able to significantly inhibit weight loss, increase non-fasting blood glucose and improve the forepaw grip strength of cachectic mice, thereby relieving the cachexia symptoms and improving the tumor-bearing survival rate of cachectic mice, and significantly increased treatment tolerance and extended survival in combination with anti-tumor therapies.

Currently, there are no GDF15 or GFRAL-targeted drugs available on the market worldwide. The Product has the potential to become an effective drug for the treatment of cancer cachexia, providing a promising clinical development value.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dongchen
Chairman

Hong Kong, 22 April 2025

As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. PAN Weidong, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin and Mr. CHEN Weiping as executive directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as independent non-executive directors.

** For identification purposes only*